Eisai announces Phase 3 Lenvima combination trial analyses in advanced kidney cancer at ESMO 2026

By Public Technologies
  • Eisai will present final Phase 3 LITESPARK-011 results for advanced kidney cancer at ESMO in Madrid on October 25, 2026.
  • The study supported recent FDA clearance of Welireg with Lenvima for adults with advanced clear-cell kidney cancer previously treated with immunotherapy.
  • LITESPARK-012 findings, also scheduled for October 25, will assess two investigational first-line regimens against Keytruda with Lenvima in advanced clear-cell kidney cancer.
  • An exploratory LEAP-001 biomarker analysis in advanced or recurrent endometrial cancer will be presented October 23, examining treatment response.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eisai Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610150808PR_NEWS_USPR_____NY72423) on October 15, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.